NCT00585182View on ClinicalTrials.gov

Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT

PHASE4CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

ObesityVenous ThrombosisAnticoagulants

Interventions

DRUG

Enoxaparin 0.5 mg/kg once daily

Enoxaparin 0.5 mg/kg (kg= actual body weight) subcutaneous once daily for 2 doses.

Trial Locations (1)

84132

University of Utah, Salt Lake City

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Sanofi

INDUSTRY

lead

University of Utah

OTHER